The chlorthalidone component in Edarbyclor (azilsartan/chlorthalidone) does pass through breast milk and could cause potentially dangerous problems in a nursing infant. No research has been done on the azilsartan component, so it is unknown whether it would also cause complications. Due to the possible risks, women should talk to their healthcare provider before breastfeeding while taking Edarbyclor.
Chlorthalidone, one of the components of Edarbyclor, is known to pass through breast milk in small amounts. Because this component is cleared from the body slowly, it could accumulate, especially in a premature baby or newborn, and potentially cause serious problems. In addition, chlorthalidone may decrease breast milk production.
No studies have been done to see if azilsartan, the other medication in Edarbyclor, passes through breast milk. Because of the lack of information, it is unknown if this medication is safe for use in women who are nursing.
Talking With Your Healthcare Provider
You should discuss breastfeeding and Edarbyclor use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click